<DOC>
	<DOCNO>NCT02947581</DOCNO>
	<brief_summary>Taenia solium neurocysticercosis ( NCC ) parasitic infection cause much neurological disease world . When parasite locate cavity around brain ( subarachnoid NCC , SANCC ) , becomes aggressive , progressive frequently lethal presentation . Current treatment regimen SANCC quite limit efficacy . The investigator propose compare current standard care ( single antiparasitic drug , albendazole ) combine regimen use two antiparasitic drug simultaneously add praziquantel . The trial enrol 164 patient four center , two Peru , one Ecuador , one Brasil .</brief_summary>
	<brief_title>Sub Arachnoid Neurocysticercosis Treatment Outcome ( SANTO )</brief_title>
	<detailed_description>Double-blind , randomize , placebo-controlled study patient subarachnoid cysticercosis basal cisterns Sylvian fissure , compare two parallel arm efficacy standard care anti-parasitic regime ( 30 day ABZ 15 mg/k/d , 1200 mg/k/d ) combine regime use similar dos ABZ add PZQ 50 mg/k/d initial 15 day anti-parasitic treatment . The study interim analysis plan design allow direct , concrete efficacy comparison deadly type NCC minimize risk disease progression standard care arm . In short , parallel group study dichotomous primary outcome variable . The main analysis compare proportion patient obtain primary outcome 6 month , use Chi-square test bivariate analysis . A similar analysis use proportion patient good clinical outcome , proportion patient lesion resolution sustains assess month 12 . A Student T test analysis use compare reduction parasite volume non-parametric Mann-Whitney test alternatively apply non-normally distribute data . A non-parametric Spearman 's Rho test use assess correlation proportion cyst mass reduction decrease antigen level study group . A Chi-square test bivariate analysis evaluate association negative antigen level 6 month versus complete disappearance cyst mass .</detailed_description>
	<mesh_term>Neurocysticercosis</mesh_term>
	<mesh_term>Cysticercosis</mesh_term>
	<mesh_term>Taeniasis</mesh_term>
	<mesh_term>Albendazole</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Male female adult individual ( 18 65 y.o . ) diagnosis basal subarachnoid cysticercosis ( include location Sylvian fissure lower interhemispheric space ) neuroimaging confirm serology . Baseline laboratory result along acceptable range ( specifically define study protocol ) . Willingness accomplish twoweek minimum hospitalization require . Previous therapy ABZ PZQ precede 3 year ( except patient receive singledose ABZ intestinal parasite , patient receive antiparasitic treatment one three year enrollment demonstrate lesion persistence progression past 12 month ) . A type NCC expose patient increase risk study , specifically : ) intraventricular cyst ; b ) cysts brainstem ; c ) concomitant intraparenchymal lesion great 3 cm diameter addition SANCC lesion ; ) 20 intraparenchymal cyst addition SANCC lesion ; ) untreated ocular cysticercosis . Patients lateral ventricle cyst , less 2 cm diameter , without hydrocephalus intracranial hypertension , include . The presence concomitant intraparenchymal cyst le 3 cm diameter exclude patient unless 20 . Active pulmonary tuberculosis evidence positive chest Xray positive sputum smear , symptom compatible tuberculosis ( fever+sweats fever+cough ) otherwise explain . Individuals positive marker active hepatitis . Systemic disease may affect therapy shortterm prognosis , include limited chronic renal failure , hepatic insufficiency , cardiac failure , steroiddependent immune disease . Patients unstable condition symptomatic intracranial hypertension ( ICH ) . Definition symptomatic ICH study presence headache , nausea , vomit , papilledema fundoscopic examination . Patients category consider entrance study resolution ICH ventricularperitoneal shunt neuroendoscopic procedure involve CSF flow derivation . These procedure would do part standard medical care part trial intervention . Pregnancy antiparasitic treatment . If patient becomes pregnant treatment , continue study radiological exam delay delivery . History hypersensitivity ABZ PZQ Chronic drug abuse define study protocol . Unwilling unable undergo MRI exam ( like patient ferromagnetic implant ) Inability unwillingness subject legal representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>subarachnoid neurocysticercosis</keyword>
	<keyword>albendazole</keyword>
	<keyword>praziquantel</keyword>
</DOC>